KRAS biomarker testing disparities in colorectal cancer patients in New Mexico

INTRODUCTION: American Society of Clinical Oncology (ASCO) guidelines recommend that all patients with metastatic colorectal cancer (mCRC) receive KRAS testing to guide anti-EGFR monoclonal antibody treatment. The aim of this study was to assess for disparities in KRAS testing and mutational status....

Descripción completa

Detalles Bibliográficos
Autores principales: Greenbaum, Alissa, Wiggins, Charles, Meisner, Angela LW, Rojo, Manuel, Kinney, Anita Y, Rajput, Ashwani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701808/
https://www.ncbi.nlm.nih.gov/pubmed/29202108
http://dx.doi.org/10.1016/j.heliyon.2017.e00448

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701808/
https://www.ncbi.nlm.nih.gov/pubmed/29202108
http://dx.doi.org/10.1016/j.heliyon.2017.e00448

Ejemplares similares